At Merus, we know that time is of the essence. Every day, we bring a sense of urgency and a passion to help patients, by working towards discovering and…

At Merus, we are clinically advancing leading-edge, targeted treatments to address the unmet needs of patients with various types of cancer.

The product candidates in the Merus pipeline are based on the Multiclonics ® format (full length human IgG antibodies). Our strategy employs the unique attributes of our proprietary bispecific antibodies and our patented screening technologies to engage and harness the power of the immune system to target tumor cells.

Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics ®.

Fabian Zohren, M.D., Ph.D. has served as our Chief Medical Officer since July 2024. His responsibilities include leading clinical development at Merus. Dr. Zohren is a proven late-stage clinical development expert and most recently he was Chief Medical Officer at ImmunoGen from November 2023 through its acquisition by AbbVie in May 2024.

This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Merus’ most recent Annual Report on Form 10-K and in Merus’ other periodic reports on Form 10-Q and Form 8-K filed with the SEC, and actual results may vary materially.

Merus is committed to discovering and developing new treatments. Every day, we bring a sense of urgency and a passion to help patients.

Apr 17, 2023 · T Cell EngagersMerus Platform Technology

Merus N.V. Uppsalalaan 17 3 rd & 4 th floor 3584 CT Utrecht The Netherlands +31 85 016 2500 [email protected]

Dec 31, 2019 · “In this interim dataset, petosemtamab in combination with pembrolizumab has demonstrated clinically meaningful activity in first line head and neck cancer, with a 67% …